文献速递细菌感染、耐药与抗菌药物

来法莫林:用于社区获得性细菌性肺炎的新型半合成截短侧耳素类抗生素

Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
PubMed 文献 · Clin Infect Dis · 2020-01-01

社区获得性细菌性肺炎(CABP)仍是全球重要致病和致死原因,抗菌药物耐药持续蔓延,亟需新型抗生素。来法莫林(原BC-3781)是一种半合成截短侧耳素类抗生素,获FDA批准用于成人CABP治疗,有口服和静脉两种剂型,对典型和非典型CABP病原体均有强体外活性。本文综述来法莫林现有数据,包括两项III期临床试验(LEAP 1和LEAP 2)的最新证据,并讨论其在CABP治疗中的潜在作用。

要点

  • 来法莫林获FDA批准用于成人CABP,有口服和静脉两种剂型。
  • 来法莫林对典型和非典型CABP病原体均有强体外活性。
  • 来法莫林是首个全身用于人类的截短侧耳素,机制为抑制蛋白合成。

核心结论

  • 来法莫林是一种新型半合成截短侧耳素类抗生素,获FDA批准用于成人CABP治疗,对典型和非典型CABP病原体均有强体外活性。

研究设计与样本

  • 本文为综述,汇总来法莫林现有数据,包括两项III期临床试验(LEAP 1和LEAP 2)的最新证据。

主要发现

  • 来法莫林有口服和静脉两种剂型,对典型和非典型CABP病原体均有强体外活性。
  • 来法莫林是首个全身用于人类的截短侧耳素,通过阻止tRNA结合进行肽转移而抑制蛋白合成。

临床怎么用

  • 来法莫林可作为成人CABP的治疗选择,兼顾口服和静脉给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Community-acquired bacterial pneumonia (CABP) remains a significant cause of morbidity and mortality worldwide. Antimicrobial resistance, including in pathogens that cause CABP, continues to spread at an alarming rate. Because of these factors, the development of new antibiotic classes is urgently needed. Lefamulin, previously known as BC-3781, is a semisynthetic pleuromutilin antibiotic that was approved by the Food and Drug Administration for the treatment of CABP in adults. Available in both oral and intravenous formulations, lefamulin has potent in vitro activity against both typical and atypical CABP pathogens. The first pleuromutilin to be used systemically in humans, lefamulin has a unique mechanism of action that inhibits protein synthesis by preventing the binding of tRNA for peptide transfer. This review summarizes the available data on lefamulin, including recent evidence from 2 phase III clinical trials (LEAP 1 and LEAP 2), and discusses its potential role in the treatment of CABP.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Watkins RR, File TM. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia. Clin Infect Dis. 2020. PMID: 32221520. doi:10.1093/cid/ciaa336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。